TIM-3 Assay Portfolio Service
T-cell immunoglobulin and mucin domain 3 (TIM-3) is a potential target in cancer immunotherapy due to its expression on a variety of T cells. With advanced and high-end technologies, rich experienced scientists, Creative Biolabs is an excellent service provider in the field of tumor marker assay. After long years of research to fully comprehend tumor markers, we launched our TIM-3 assay portfolio service, which can be useful in targeted cancer therapy and diagnosis.
Background What We Can Offer Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Critical Role of TIM-3 in the Tumor Microenvironment
TIM-3 (HAVCR2) is an immune checkpoint receptor with four key ligands in cancer: Galectin-9, phosphatidylserine (PtdSer), high-mobility group protein box 1 (HMGB1), and Carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM-1). Its signaling is regulated by Bat3 and Lck kinase. Binding to Galectin-9 induces T-cell suppression and promotes leukemic stem cell self-renewal via NF-κB/β-catenin pathways. TIM-3 is expressed across many cancers and correlates with poor prognosis in AML/MDS. Anti-TIM-3 antibodies can block these interactions, restore immune function, and promote antibody-dependent phagocytosis of tumor cells by macrophages, highlighting their therapeutic potential.
Fig.1 Cells expressing TIM-3 in the glioblastoma microenvironment. 1, 3
TIM-3 Assay Portfolio at Creative Biolabs
Understanding the complex mechanisms of TIM-3 requires a multifaceted approach. At Creative Biolabs, our TIM-3 assay portfolio service is a meticulously designed program that covers every stage of drug development, from target validation to preclinical assessment. Our platform is built on cutting-edge technologies and a deep understanding of immune checkpoint biology, ensuring robust and reproducible data for your project.
For a detailed discussion on how our TIM-3 assay services can advance your specific research project, please contact us today.
Publication
This review explores TIM-3 as a promising next-generation target for cancer immunotherapy. It summarizes TIM-3's role as an immune checkpoint molecule that mediates tolerance and exhaustion in T cells and other immune cells within the tumor microenvironment. The article details its molecular structure, ligands, and complex signaling mechanisms, which can be both inhibitory and stimulatory. It highlights the potential of anti-TIM-3 antibodies, particularly in combination with existing PD-1/CTLA-4 blockade, to overcome resistance and enhance anti-tumor immunity, while acknowledging the need for further mechanistic studies.
Fig.2 The TIM-3 immune checkpoint: A complex of ligands and adaptors in signal transduction. 2, 3
Why Choose Us?
Creative Biolabs is a strategic partner in biopharmaceutical innovation, distinguished by its decades of scientific expertise and a commitment to customization and flexibility. With a dedicated team of Ph.D.-level scientists and advanced platforms, they offer a comprehensive understanding of immune checkpoint biology, providing reliable and clinically relevant data. Our fully customizable services are designed to streamline research, accelerate the path to clinical success, and de-risk the pipeline. By leveraging their expertise, you can make informed decisions and develop the next generation of life-changing cancer immunotherapies.
Discover how we can help your project succeed. Request a consultation today to begin the conversation about your specific goals.
FAQs
Q1: What types of therapeutic candidates can you test with your TIM-3 assays?
A1: Our assays are designed to be highly flexible and can accommodate various therapeutic candidates, including monoclonal antibodies, bispecific antibodies, and small molecules that target the TIM-3 pathway.
Q2: How can your assays help me overcome resistance to anti-PD-1/PD-L1 therapies
A2: TIM-3 signaling is a known mechanism of resistance to PD-1/PD-L1 blockade. Our combination assays, where we test your candidate in conjunction with existing immunotherapies, can help you identify a therapeutic strategy to restore T-cell function and overcome this acquired resistance.
Q3: What if my project requires additional services, such as protein production
A3: We offer a full suite of complementary services, including recombinant protein expression and antibody development. We can provide a comprehensive, integrated solution for your entire drug discovery and development pipeline.
Customer Review
-
High-Quality Data
Creative Biolabs' TIM-3 assay portfolio in our research has significantly improved our ability to assess the in vitro potency of our therapeutic antibody candidates. The data quality was outstanding and directly supported our lead optimization efforts. - Jn S*th
-
Valuable Insight
The expert consultation after the project was invaluable. It helped us understand subtle nuances in our data that we might have otherwise missed. Using Creative Biolabs' TIM-3 assay portfolio has greatly facilitated our understanding of immune synapse disruption caused by TIM-3. - Aa J*s
Related Services
Our TIM-3 assay portfolio can be integrated with a variety of our other services to provide a complete solution for your research and development needs.
B Cell-based Cross Blocking Assay
Creative Biolabs offers blocking assays, also known as antibody competition assays, for clients to study cancer antigens and identify immunodominant epitopes using epitope-specific antibodies.
Learn More →
Small Animal In Vivo PK Service
Creative Biolabs offers one-stop in vivo drug research services for small animal models. Our services are designed to assist clients from the start of their project to achieve their experimental goals.
Learn More →
Contact Us
Creative Biolabs is your trusted partner for accelerating the discovery and development of next-generation cancer immunotherapies. By leveraging our comprehensive TIM-3 assay portfolio and deep scientific expertise, you can confidently advance your most promising therapeutic candidates.
We encourage you to reach out to our team to discuss your specific molecule and determine the most suitable assays.
References
-
Ahmady, Farah, et al. "The Role of TIM-3 in Glioblastoma Progression." Cells 14.5 (2025): 346. https://doi.org/10.3390/cells14050346
-
Du, Wenwen, et al. "TIM-3 as a target for cancer immunotherapy and mechanisms of action." International journal of molecular sciences 18.3 (2017): 645. https://doi.org/10.3390/ijms18030645
-
Distributed under Open Access license CC BY 4.0, without modification.
